– UK, Edinburgh – Cumulus Oncology, an oncology and inflammation-focused biotech, announced the addition of Dr. Manuel Aivado (MD, Ph.D.) to its Board of Directors .
About Dr. Manuel Aivado
Dr. Manuel Aivado is a board-certified haematologist and oncologist with extensive experience in the pharma and biotech drug development field. He brings deep insights into the key features driving successful drug approvals, including the evaluation of unmet medical need. Manuel has been integrally involved in the strategic and operational aspects of six new drug approvals (NDAs), including four in oncology, in recent years. He has a strong track record in successful clinical development strategies as well as successful business management based on his operational experience steering and guiding other private and public companies as an Executive or Board Director.
About Cumulus Oncology
Cumulus Oncology is developing a portfolio of assets targeting known and novel pathways in oncology and inflammation. The company creates novel oncology asset opportunities via its internal ideation function, supplemented by asset ID and acquisition from a range of sources, including academic institutes, commercial drug discovery groups, and biopharmaceutical companies. An early focus on molecularly selected patient sub-groups is a key aspect of the company’s strategic focus. The company incorporates the use of a range of tools, including artificial intelligence (AI) and machine learning (ML) platforms, into its decision-making process to prioritize targets and assets and build patient sub-group hypotheses.
Cumulus currently has a portfolio of four assets focused on areas of high scientific validation and active pharma company deal activity. This includes assets in the DDR area, a focus on GPCRs in the oncology and inflammation areas, as well as novel targets and assets within well-defined pathways where both a precision medicine approach and clinical proof of concept exist.
The founding team at Cumulus consists of successful life science entrepreneurs, scientists, and a range of oncology drug development and pharma sector business professionals who have collectively taken ten oncology assets to successful drug approval.
For more information: https://cumulusoncology.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.